Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on September 21, 2016. The filing reports the closing of two previously announced capital raising events: a public underwritten offering and a registered direct offering.
Key Financial Metrics
The filing details the following transaction metrics regarding the equity offerings:
- Total Shares Sold: 3,403,125 shares of common stock.
- Offering Price: $3.20 per share.
- Underwriters' Option: The underwriters fully exercised their option to purchase additional shares.
Note: This filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity positions. It focuses solely on the equity transaction.
Material Changes
The primary material change reported is the increase in outstanding common stock and the associated capital raised through the combined Offerings. The filing confirms the full exercise of the underwriters' option, indicating strong demand or a strategic decision to maximize capital raised at the $3.20 price point.
Guidance, Outlook, and Risks
The filing text does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard incorporation of the press release (Exhibit 99.1). No unusual items were disclosed in the text of this report.
Investor Verification Checklist
- Verify the total gross proceeds calculated from 3,403,125 shares at $3.20 per share.
- Review the attached Press Release (Exhibit 99.1) for details on the intended use of proceeds.
- Confirm the updated total number of outstanding shares post-offering in subsequent filings.
- Check for any underwriting discounts or commissions that would reduce the net proceeds to the company.